Healthcare Resource Utilization (Hcru), Costs, And Mortality In Relation To Select Immune-Related Adverse Events (Iraes) And Line Of Therapy (Lot) In Patients (Pts) With Advanced Or Metastatic Urothelial Cancer (Uc) Treated With Immune Checkpoint Inhibitor (Ici) Monotherapy.

Saby George,Ying Zheng,Elizabeth Bell,Nicole Engel-Nitz,John C White,Lincy S. Lal,Mo Yang,Geeta Devgan,Jodi Smith,Ruth Kim,Frank Xiaoqing Liu

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 0|浏览5

暂无评分

摘要

427Background: Data on HCRU and costs in US UC patients treated with ICIs is in its infancy, as there is little information by LOT or focused on irAEs due to ICI use. In addition, the relationship ...

查看译文

关键词

immune-related checkpoint inhibitor,metastatic urothelial cancer,ici,monotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要